These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 28346203)

  • 1. U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.
    Yoch D
    Int J Pharm Compd; 2017; 21(2):95-102. PubMed ID: 28346203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basics of Sterile Compounding. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 2.
    Martin M
    Int J Pharm Compd; 2018; 22(6):475-478. PubMed ID: 30384348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies.
    Kastango ES
    JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory considerations of United States Pharmacopeia Chapter <71> sterility tests and its application to pharmaceutical compounding.
    Hyde TD
    Int J Pharm Compd; 2014; 18(1):46-52. PubMed ID: 24881341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality Assurance and Quality Control, Part 2.
    Akers MJ
    Int J Pharm Compd; 2015; 19(3):215-21. PubMed ID: 26714362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Choosing a Vial Processing Line for Aseptic Compounding: Part 1.
    Noorian S; Vahedi N
    Int J Pharm Compd; 2016; 20(4):283-292. PubMed ID: 28333673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA inspections find unsafe practices in compounding pharmacies.
    McCarthy M
    BMJ; 2013 Apr; 346():f2414. PubMed ID: 23592476
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1.
    Martin M
    Int J Pharm Compd; 2018; 22(5):401-404. PubMed ID: 30384338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compounding interest: a tragedy caused by contaminated steroids turned the spotlight on compounding pharmacies.
    Hinkley KN
    State Legis; 2013 Jun; 39(6):22-3. PubMed ID: 23805443
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance Improvement in 503A Compounding Pharmacies: A PLAN FOR ASSESSMENT, IMPLEMENTATION, AND SUSTAINED SUCCESS.
    Pritchett J; Mixon W; O'Connell K
    Int J Pharm Compd; 2016; 20(1):29-36. PubMed ID: 27125054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines.
    Allen LV
    Int J Pharm Compd; 2016; 20(4):351. PubMed ID: 28333682
    [No Abstract]   [Full Text] [Related]  

  • 14. The potential impact of USP 797 and what the JCAAI is doing about it.
    Nathan R
    Allergy Asthma Proc; 2007; 28(2):236-7. PubMed ID: 17479611
    [No Abstract]   [Full Text] [Related]  

  • 15. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulating compounding pharmacies after NECC.
    Outterson K
    N Engl J Med; 2012 Nov; 367(21):1969-72. PubMed ID: 23134357
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.